UT Austin relocates its $2.5B medical center from downtown to Northwest Austin’s Domain area due to space and integration issues.

St. Jude's CEO James Downing will step down in late 2026 after 12 years, transitioning to a faculty role as a search for his successor begins.

CEO Marshall Perkins boosted his stake in MDCE to 66.2M shares via open-market buys at $0.0002, affirming confidence in the company’s AI medical screening strategy.

Three Annexon insiders sold $104K in stock Feb 18, reducing stakes by 6.5%-7.5%, as shares closed at $4.90 on Feb 20.

A pharmacist suggests a mineral may help prevent 3 a.m. wake-ups, but details and evidence were lacking.

The FDA approved BYSANTI, a new antipsychotic for bipolar mania and schizophrenia, with a U.S. launch expected in Q3 2026.

Medicare will now cover FDA-approved multicancer blood/saliva tests, boosting approval efforts despite cost and accuracy challenges.

REGENXBIO faces lawsuit for misleading investors about RGX-111 gene therapy safety, after FDA halted trials due to a participant’s brain tumor.

Fabtech wins ₹63.6 crore contract to build a GMP-compliant pharma plant in West Africa, boosting local medicine production.

AstraZeneca blocked Pharmacor’s generic diabetes drug launch in Australia with a court order, protecting its patent until a full trial.